FILE:BMY/BMY-8K-20041216145839.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
Table of Contents
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (General Instruction A.2. below):
see
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
Table of Contents
Item 8.01. Other Events.
On December 14, 2004, Bristol-Myers Squibb Company announced it signed a definitive agreement to sell its Oncology Therapeutics Network (OTN) unit to One Equity Partners LLC. The transaction is expected to be completed during the first quarter of 2005, pending certain regulatory approvals. A copy of the press release is attached to this report as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
     
(c) Exhibits
     99.1 Press Release, dated December 14, 2004, of Bristol-Myers Squibb Company.
Table of Contents
SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXHIBIT INDEX

 
Exhibit 99.1
(New York, December 14, 2004)  Bristol-Myers Squibb Company (NYSE: BMY) has signed a definitive agreement to sell its Oncology Therapeutics Network (OTN) unit to One Equity Partners LLC. It is expected that this transaction will be completed during the first quarter of 2005, pending certain regulatory approvals.
The divestiture of OTN will further enable Bristol-Myers Squibb to focus on its strategic priorities in developing its pipeline and new product opportunities in ten disease areas of significant unmet medical need.
OTN is a leading specialty distributor of pharmaceuticals to office-based oncologists. For the year ended December 31, 2003, OTN generated revenues of $2.2 billion and earnings before minority interest and income taxes of $14 million.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Specifically, there can be no guarantee that the transaction described in this release will receive the required regulatory approvals. For further details and a discussion of this and other risks and uncertainties, please see the company's 2003 Annual Report on Form 10-K/A and in the company's periodic reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


